Immune effector cell surface glycoconjugates

Immune effector cell surface glycoconjugates are a diverse group of carbohydrate-modified molecules, including glycoproteins and glycolipids, that form the glycocalyx on the surface of cells like T cells and Natural Killer (NK) cells (Palleon Pharmaceuticals, 2024). These glycoconjugates serve as critical regulators of immune homeostasis by acting as ligands for glycan-binding proteins, such as Siglecs and Galectins, which transmit inhibitory or activating signals (Nature Chemical Biology, 2020). In many cancers, the upregulation of specific glycans, particularly those terminated with sialic acid, creates a "glyco-immune checkpoint" that suppresses the activity of immune effector cells, allowing the tumor to evade destruction (Frontiers in Immunology, 2023). Therapeutic interventions targeting these glycoconjugates, such as the sialidase fusion protein E-602, aim to enzymatically remove inhibitory sialic acids to restore the immune system's ability to recognize and kill cancer cells (ClinicalTrials.gov, 2023). Beyond oncology, these glycoconjugates are involved in leukocyte trafficking and inflammatory signaling, making them relevant targets for treating autoimmune and chronic inflammatory conditions (Trends in Immunology, 2018).

Other names

Immune cell surface glycansImmune cell glycocalyxGlyco-immune checkpoint ligandsSialylated glycoconjugatesSiglec ligandsGalectin ligands

Enzymatic desialylation of cell surface glycans to remove inhibitory signals and enhance immune effector function; competitive inhibition of glycan-lectin interactions.